Manna Soumyarwit, Augsburger James J, Correa Zelia M, Al-Rjoub Marwan F, Rao Marepalli B, Banerjee Rupak K
1 Department of Mechanical and Materials Engineering, University of Cincinnati , Cincinnati, Ohio.
2 Department of Ophthalmology, University of Cincinnati , Cincinnati, Ohio.
J Ocul Pharmacol Ther. 2016 Nov;32(9):583-594. doi: 10.1089/jop.2016.0006. Epub 2016 Oct 18.
The purpose of this study is to noninvasively evaluate the safety and toxicity of a chitosan (CS) and polylactic acid (PLA)-based sustained-release methotrexate (MTX) intravitreal microimplant in normal rabbit eyes using electroretinography (ERG).
PLA-coated CS-based microimplants containing 400 μg of MTX and placebo microimplants (without drug) were surgically implanted in the vitreous of the right and the left eyes, respectively, in each of the 8 New Zealand rabbits using minimally invasive technique. At each predetermined time points (days 5, 12, 19, and 33), ERG was conducted on 2 rabbits to evaluate the safety of the microimplants administered in each eye. ERG was carried out using 2 protocols, scotopic and photopic, on each eye prior to surgery (PS) and prior to euthanasia (PE) conditions. The safety of the microimplants was assessed using statistical analysis of the ERG data (B/A ratio analysis, oscillatory potential analysis, and Naka-Rushton analysis) and subsequently quantifying and comparing functional integrity of the retina between the PS and PE conditions of each eye.
Statistical analysis of the ERG data showed no change in retinal functional integrity because of the PLA-coated CS-based MTX microimplant and the placebo microimplant. ERG analysis also revealed absence of any evident bioelectrical dysfunction caused by the microimplants.
ERGs were performed to determine whether the microimplants containing MTX and the placebo microimplants were associated with any profound retinal bioelectrical dysfunction that might be attributable to toxicity not apparent on histological studies of such eyes. The results shown in this report indicate that there were no such evident adverse effects of the microimplants or contained drug.
本研究旨在使用视网膜电图(ERG)对基于壳聚糖(CS)和聚乳酸(PLA)的甲氨蝶呤(MTX)缓释玻璃体内微植入物在正常兔眼中的安全性和毒性进行无创评估。
采用微创技术,将含有400μg MTX的PLA包被的CS基微植入物和安慰剂微植入物(不含药物)分别手术植入8只新西兰兔每只兔子的右眼和左眼玻璃体内。在每个预定时间点(第5、12、19和33天),对2只兔子进行ERG检查,以评估每只眼睛中所给药的微植入物的安全性。在手术前(PS)和安乐死前(PE)状态下,对每只眼睛使用暗视和明视两种方案进行ERG检查。通过对ERG数据进行统计分析(B/A比值分析、振荡电位分析和中谷-拉什顿分析),并随后量化和比较每只眼睛PS和PE状态之间视网膜的功能完整性,来评估微植入物的安全性。
ERG数据的统计分析表明,基于PLA包被的CS的MTX微植入物和安慰剂微植入物并未导致视网膜功能完整性发生变化。ERG分析还显示,微植入物未引起任何明显的生物电功能障碍。
进行ERG检查是为了确定含有MTX的微植入物和安慰剂微植入物是否与任何可能归因于毒性的严重视网膜生物电功能障碍相关,而这种毒性在对此类眼睛的组织学研究中并不明显。本报告所示结果表明,微植入物或所含药物没有此类明显的不良反应。